ZAP70 and B-cell chronic lymphocytic leukemia: Since treatment with ibrutinib decreased the OCR of CLL cells to levels comparable to B lymphocytes, and that ZAP-70-positive cells are more sensitive to FCCP, one may postulate that ZAP-70+ cells would be more sensitive to treatments such as ibrutinib or combinations [22].